UCB 7665

Drug Profile

UCB 7665

Alternative Names: UCB7665

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator UCB
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Immune thrombocytopenic purpura; Myasthenia gravis
  • Phase I Immunological disorders

Most Recent Events

  • 18 Nov 2016 Phase-II clinical trials in Myasthenia gravis in Germany (IV) (EudraCT2016-002698-36)
  • 01 Mar 2016 Phase-II clinical trials in Immune thrombocytopenic purpura in Moldova and Spain (SC) (NCT02718716; EudraCT2015-003984-12)
  • 05 Feb 2016 Phase-II clinical trials in Immune thrombocytopenic purpura in United Kingdom, Romania, Romania, Poland, Italy, Belgium, Australia (SC) after February 2016 (EudraCT2015-003984-12) (NCT02718716)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top